There are currently 343 clinical trials in Fort Worth, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Cook Children's Medical Center, GSK Investigational Site, Cook Children's Medical Center - Fort Worth and UT Southwestern/Simmons Cancer Center-Fort Worth. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Texas Digestive Disease Consultants, Fort Worth, Texas
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
Empowering Families Project
NCT05359185
Recruiting
This RCT will test the marginal benefit of adding economic-focused services to traditional relationship education (RE) interventions. 344 couples will be randomly assigned to the RE only or RE plus economic-services condition. All couples will be assessed at baseline, 6-weeks, 6-months, and 12-months. This project will examine whether couples in the RE plus condition have better relationship and economic outcomes than couples in the RE only condition.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: The Parenting Center, Fort Worth, Texas
Conditions: Couples, Relationship, Marital, Relational Problems
Register for Updates
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT04564339
Recruiting
The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/22/2023
Locations: Clinical Study Site, Fort Worth, Texas
Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy
Register for Updates
The Pediatric Anesthesia Quality Improvement Project
NCT00674388
Recruiting
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events.
Gender:
All
Ages:
21 years and below
Trial Updated:
11/20/2023
Locations: Cook Children's Health Care System, Fort Worth, Texas
Conditions: Surgery, Anesthesia, Children
Register for Updates
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519
Recruiting
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy... Read More
Gender:
All
Ages:
Between 10 years and 25 years
Trial Updated:
10/25/2023
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: B-cell Acute Lymphoblastic Leukemia, Obesity
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Dallas Fort Worth Clinical Research Associates, Fort Worth, Texas
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility
NCT01354002
Recruiting
The aims of this protocol are: to collect and store diseased and normal tissue and body fluid samples from new and returning patients at St. Jude Children's Research Hospital (SJCRH), affiliated sites and collaborating institutions; to collect and store samples from relatives of SJCRH patients; to collect and store retrospective and prospective pertinent corresponding clinical and laboratory data on disease characterization, treatment, and outcome; and to serve as a source of human biological sa... Read More
Gender:
All
Ages:
All
Trial Updated:
10/09/2023
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Normal and Diseased Tissue and Body Fluids Samples
Register for Updates
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
NCT05875948
Recruiting
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
Gender:
All
Ages:
18 years and above
Trial Updated:
09/29/2023
Locations: Baylor Scott and White All Saints Medical Center, Fort Worth, Texas
Conditions: Hepatorenal Syndrome, Acute Kidney Injury
Register for Updates
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
NCT05568706
Recruiting
This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who are at high risk for complications after RSV infection.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Valley Institute of Research, Fort Worth, Texas
Conditions: RSV Infection
Register for Updates
Study of Kidney Tumors in Younger Patients
NCT00898365
Recruiting
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Gender:
All
Ages:
29 years and below
Trial Updated:
09/06/2023
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
Register for Updates
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
NCT05705440
Recruiting
The purpose of this follow-up study is to describe the safety in subsequent pregnancies in participants who were previously administered the RSVPreF3 maternal vaccine or control during any prior RSV MAT study. The study participants enrolled in this follow-up study received RSVPreF3 maternal vaccination (any dose) or controls during the following prior RSV MAT studies: RSV MAT-001 (NCT03674177), RSV MAT-004 (NCT04126213), RSV MAT-010 (NCT05045144), RSV MAT-011 (NCT04138056), RSV MAT-009 (NCT046... Read More
Gender:
Female
Ages:
Between 9 years and 49 years
Trial Updated:
08/30/2023
Locations: GSK Investigational Site, Fort Worth, Texas
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Targeting Endoplasmic Reticulum Stress in Human Hypertension
NCT06025630
Recruiting
There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
08/29/2023
Locations: University of North Texas Health Science Center, Fort Worth, Texas
Conditions: Hypertension
Register for Updates